Revenue ($USD) : $4,862,800,000 R&D spend : $283,400,000.00 Employees : 6,944 Fiscal year end : 09/24/22 CEO : Stephen MacMillan, president and CEO
Hologic revenue declined in fiscal 2022 but was still above pre-pandemic levels. The decline of COVID-19 testing slashed the women’s health and diagnostics company’s sales by 21% year-over-year during the first three quarters of fiscal 2023, which wraps up at the end of September 2023. However, Hologic’s breast health business grew revenues 27.4% year-over-year in Q3, aided by higher capital equipment revenue and an improving semiconductor chip supply environment. Said CEO Steve MacMillan: “Our results once again highlight that Hologic’s transformation and post-pandemic performance is durable.” –CN